Category: Stock Market

Shares in Meeka Metals Ltd (ASX: MEK) have more than halved in recent months, with the analyst team at Morgans convinced this represents an attractive buying opportunity.

Weak production disappoints

Meeka released its quarterly report late last month and revealed that gold production had fallen sharply, down from 9174 ounces in the previous quarter to 6083 ounces.

The company reported mine operating cash flow of $25.8 million and net mine cash flow of $10 million, “after significant non-recurring growth capital investment ($15.8M) in new mines and expanded infrastructure”.

The company’s cash on hand increased from $37.3 million in the December quarter to $50.1 million, with the company unhedged and holding no debt.

Meeka Managing Director Tim Davidson said regarding the quarterly:

It was a frustrating quarter from a production perspective but we did see significant improvement in process plant throughput. We expect this to continue as the mill feed transitions to increasingly fresh ore from underground over the coming quarters, which will also deliver an increase in head grade. To this end our investment in new mines, including our next underground mine at Turnberry, will further increase head grade through the plant with more targeted underground mining and less reliance on open pit ore and stockpiles. Pleasingly our cash build continued even after significant, non-recurring, capital expenditure on growth projects.

Part of the company’s production issues stemmed from significant rainfall, which impacted operations at its open pit mines, reducing access to higher grade ores.

This in turn disrupted the company’s plans to stream grades together, “resulting in an increased reliance on processing lower grade stockpiles accumulated over the preceding 12 months since mining commenced”.

Shares still looking cheap

Morgans said the quarterly also missed expectations on the cost front.

The analysts added:

We maintain our buy rating, but view the next two quarters as critical as Meeka needs to demonstrate clear grade improvements to remain on track for the anticipated step-change in free cash flow into FY27. Following a tough third quarter, the next 6 months represent a key inflection point for Meeka, where delivery of key operational milestones will determine balance sheet strength. The commencement of underground stoping in the latter part of the quarter is expected to lift grades, drive throughput efficiencies and underpin stronger cashflow into FY27.

Morgans said in addition to the current operations, they expected further high grade exploration success and resource conversion.

Morgans has a price target of 35 cents on Meeka shares compared with the current price of 13.25 cents.

Meeka is valued at $412.4 million.

The post Morgans says this sold down ASX gold company could more than double in value appeared first on The Motley Fool Australia.

More reading

• What are experts saying about these shares hitting 52-week lows 
• 5 things to watch on the ASX 200 on Tuesday
• 3 ASX ETFs that have raced ahead this year
• Could Macquarie shares be the best ASX financial stock to buy?
• Is now the time to turn to high yield dividend shares?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The team at Bell Potter have been covering ASX small-cap EMvision Medical Devices Ltd (ASX: EMV) for some time. 

Over that period, it has drawn positive ratings from the broker.

Like many ASX small-cap healthcare stocks, a large part of its valuation and future success depends on whether its clinical trials produce strong results.

Company overview 

EMvision was established in 2017 and listed on the ASX in 2018. It aims to change the Stroke Care paradigm to positively impact the lives of millions globally.

The lead product in development is a portable, cost-effective, non-ionising and safe brain scanner. The scanner is capable of rapidly determining the presence of suspected stroke and stroke type to provide game-changing insights for clinicians. 

The lead product is a hospital and cart-based device that can be wheeled around and used by Stroke Centres, Intensive Care Units and Emergency Departments, called emu. 

A new report from Bell Potter has updated its view following a key clinical trial update for the ASX small-cap. 

Fresh clinical trial update

According to the report, EMvision is expanding its main clinical trial so its brain scanner can detect:

• bleeding strokes (haemorrhagic), and now also
• blocked-vessel strokes (ischaemic).

That matters because only about 13% of strokes are bleeding strokes, while about 87% are ischaemic strokes.

In short, EMvision is trying to make its device useful for almost all stroke patients, not just a small subset.

While correctly identifying c.13% of strokes is valuable, having a further indication that covers detecting ischaemic strokes (c.87%), would enhance clinical utility and commercial value. 

Adding the additional indication is expected to add a relatively modest amount of time to the Pivotal trial’s timelines, with enrolment now expected to be completed in late CY26 / early CY27.

The broker said at present 125 patients have been enrolled across multiple sites with a target of 300 patients. 

Including the ischaemia detection endpoint in the current Pivotal Trial leverages the same patient cohorts, infrastructure, and regulatory pathway to generate expanded indications, potentially saves up to two years and several million dollars in trial costs compared to funding and enrolling a standalone trial later.

Steady progress

Following the update, Bell Potter has retained its buy recommendation on this ASX small-cap. 

It also has retained its price target of $3.15. 

From yesterday’s closing price of $1.89, this indicates an upside potential of approximately 67%. 

EMV continues to make steady progress in its Pivotal Trial and other studies. Despite extending the trial timeline, adding in ischaemia as a primary endpoint, seems wise from a cost, timeline and commercial value perspective. 

One can infer a timeline for the readout at 3QFY27, followed by an FDA decision on the De Novo application in 1H28.

The post What is Bell Potter’s view on this ASX small-cap following a clinical trial update? appeared first on The Motley Fool Australia.

More reading

• Is this ASX gold stock a buy, hold or sell after its quarterly results?
• Is this ASX energy stock a buy, hold or sell following quarterly results?
• Here’s why Morgans just upgraded Woolworths shares
• Bell Potter says this ASX real estate stock could rise 33%
• Top 10 ASX shares bought and sold in April

Motley Fool contributor Aaron Bell has positions in EMVision Medical Devices. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended EMVision Medical Devices. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Broker recommendations should never be followed blindly.

Analysts can be wrong, price targets can change, and even high-quality companies can disappoint.

But I still think broker views can be useful when they highlight businesses where the market may be focusing too heavily on short-term uncertainty and not enough on long-term value.

Three ASX 200 shares currently attracting buy ratings are named in this article.

Pinnacle Investment Management Group Ltd (ASX: PNI)

Pinnacle Investment Management is one ASX share that Morgans remains positive on.

The investment house recently reviewed Pinnacle’s third-quarter update and kept its buy rating on the stock. It also lifted its target price to $24.70 from $23.21.

The key point from Morgans was that Pinnacle’s flows were stronger than expected during the quarter, despite a volatile market environment. I think that is important.

Fund managers can be very sensitive to market conditions. When sentiment weakens, investors may pull money out, delay allocations, or shift into more defensive options. So, when a funds management business is still attracting flows in a difficult backdrop, it can say something useful about the strength of its affiliates, investment performance, and client relationships.

Morgans also noted Pinnacle’s additional 6.8% investment in Metrics, describing it as a further vote of confidence in the business.

This is the part I like about Pinnacle. It is not a traditional single-manager funds business. It backs a range of specialist investment managers, which gives it exposure to multiple strategies and growth opportunities.

That does not remove risk. Markets still matter, performance fees can move around, and investor flows can be cyclical. But if Pinnacle keeps supporting quality affiliates and growing funds under management over time, I think it remains an attractive long-term financial stock.

Flight Centre Travel Group Ltd (ASX: FLT)

Flight Centre is a much more contrarian idea. Morgans has a buy rating and a $14.55 target price on the travel company, even though it has concerns about near-term trading.

The broker noted that Flight Centre surprisingly maintained its FY26 earnings guidance, despite the Middle East conflict creating uncertainty and temporarily disrupting international travel patterns. It also pointed out that the impact has been more significant in leisure travel, with April profit down around $10 million on the prior corresponding period.

That clearly shows there is risk here. Travel shares can be vulnerable to geopolitical shocks, consumer weakness, fuel prices, airline capacity, and currency movements.

But I can see why Morgans is still looking through the current disruption.

Its view is that Flight Centre would have had a great year without the conflict, given its results for the first nine months were strong. Morgans also believes the company is worth materially more than the current share price after the earnings downgrade. That is the opportunity.

Travel demand has shown many times that it can rebound after downturns. If the current disruption proves temporary, Flight Centre could eventually benefit from normalising conditions, corporate travel recovery, and pent-up demand from consumers who still want to travel.

It is not a low-risk buy, but I think it is an interesting recovery stock for investors willing to be patient.

ARB Corporation Ltd (ASX: ARB)

ARB Corporation is another ASX share with broker support, with Ord Minnett maintaining a buy rating with a $31.00 target price.

The company is best known for its four-wheel drive accessories, including bull bars, suspension, canopies, recovery equipment, and camping-related products.

Ord Minnett acknowledged near-term headwinds. New vehicle sales have been affected by inconsistent manufacturer supply, and elevated fuel prices may weigh on demand for ARB’s Australian aftermarket operations.

But the longer-term outlook appears more appealing.

The broker highlighted robust demand for ARB’s products, a healthy order book, and new vehicles and products being released globally. It also expects earnings growth to be supported by new and refurbished stores, offshore expansion, and strategic partnerships with original equipment manufacturers.

I think that is the right way to view ARB.

Short-term demand can move with the economy, fuel prices, and vehicle sales. But ARB has built a strong brand in a niche where quality and trust matter. For many customers, four-wheel drive accessories are not just about looks. They are about safety, capability, and reliability.

That gives ARB a durable position if it keeps executing well.

Foolish takeaway

These three broker-backed ASX 200 shares offer very different investment cases.

Pinnacle is a funds management growth story. Flight Centre is a recovery opportunity. ARB is a quality brand with offshore expansion potential.

None is risk-free, and broker ratings are only one input. But I think all three have enough long-term appeal to be worth a closer look for investors searching for opportunities in the current market.

The post 3 ASX 200 shares that brokers are recommending as buys in May appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• Top brokers name 3 ASX shares to buy next week
• Buy, hold, sell: ARB, Aurizon, and Goodman shares
• 8 ASX 200 shares with renewed buy ratings this week
• Morgans says these ASX dividend shares are buys

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ARB Corporation and Pinnacle Investment Management Group. The Motley Fool Australia has positions in and has recommended Pinnacle Investment Management Group. The Motley Fool Australia has recommended ARB Corporation and Flight Centre Travel Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Inflation is back in the headlines in 2026. 

Australia’s annual headline inflation rate rose to 4.6% in the 12 months to March, up from 3.7% in February, with fuel a major driver of the increase.

For investors, this creates a simple problem. Cash sitting in the bank needs to work harder just to maintain purchasing power.

That is why I think these ASX income stocks with forecast dividend yields above 8% could be worth considering.

GQG Partners Inc (ASX: GQG)

The first ASX income stock I would look at is GQG Partners.

GQG is a global investment manager, which makes it very different from a typical ASX dividend share.

Its earnings are tied to funds under management, investment performance, market conditions, and client flows. That means the dividend is not risk-free. A weak period for markets or fund flows could put pressure on profits and payouts.

But I think GQG has a few qualities that make it appealing for income investors.

It has a capital-light model, global reach, and exposure to institutional and wholesale investors around the world. If markets remain supportive and the company continues to attract or retain client money, it has the potential to generate strong cash flows.

According to CommSec, consensus estimates show that GQG is forecast to offer a dividend yield of around 12% in both FY26 and FY27.

That puts it well ahead of the current inflation rate and gives investors a potentially attractive income stream while they wait for long-term growth.

Harvey Norman Holdings Ltd (ASX: HVN)

Harvey Norman is another ASX income stock I think could help investors fight inflation.

The retailer has been out of favour at times because discretionary spending can be sensitive to interest rates, housing turnover, and consumer confidence.

But I think Harvey Norman is more interesting than a simple retail story.

It has a well-known brand, a large store network, offshore operations, and a significant property-backed element to the business. That property exposure gives it a different feel from many other retailers.

There are risks. If households remain under pressure from rising fuel costs, higher mortgage repayments, and cost-of-living concerns, spending on furniture, electronics, and appliances could be uneven.

But for investors focused on income, the valuation and yield are the attraction.

Consensus estimates point to Harvey Norman offering a dividend yield of around 8.5% in both FY26 and FY27.

While no dividend forecast is ever guaranteed, this is a business that has been through plenty of cycles before and continued to reward shareholders.

Foolish takeaway

Inflation at 4.6% changes the income conversation.

A 4% yield may no longer feel like enough for investors trying to protect their purchasing power.

That is why I think GQG Partners and Harvey Norman are worth a closer look. Both offer forecast yields above 8% in FY26 and FY27, based on consensus estimates.

Combined, I think they could help income investors fight inflation.

The post I’d buy these ASX income stocks to beat inflation appeared first on The Motley Fool Australia.

More reading

• What are experts saying about these shares hitting 52-week lows 
• How to build a $1,000 a month passive income from the ASX
• How much do I need to invest in ASX dividend shares for a retirement income of $5,000 per month?
• The Aussie dollar just hit a 4-year high. Which ASX shares will benefit?
• Why I’d still buy these ASX dividend stocks as interest rates rise

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Harvey Norman. The Motley Fool Australia has recommended Gqg Partners. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The ASX 200 is not packed with technology shares like the Nasdaq, but I think there are still some high-quality options for investors willing to take a long-term view.

The key, in my opinion, is focusing on businesses that solve important problems, have strong customer relationships, and can keep scaling over time.

Two ASX 200 tech shares I think could beat the market over the next decade are named in this article.

TechnologyOne Ltd (ASX: TNE)

TechnologyOne is one of the quieter compounders on the ASX.

The enterprise software company serves customers in areas such as government, education, and large organisations. These customers often need dependable software for essential functions, which can make revenue relatively sticky.

I think the attraction is the repeatability of the model.

TechnologyOne has spent years moving toward software-as-a-service, which can provide more predictable revenue and better scalability over time. It is also expanding in the UK, giving the company another potential growth engine.

That overseas opportunity is important.

Australia has already been a strong market for TechnologyOne, but the UK gives it a chance to prove that its software model can travel. If it can keep winning customers there, the company may have a much larger growth runway than investors assume.

This is the kind of business that may not always grab headlines, but it can be very useful in a long-term portfolio.

NextDC Ltd (ASX: NXT)

NextDC is a very different ASX 200 tech share.

It does not sell software. It develops and operates data centres, which are becoming increasingly important infrastructure for the digital economy.

I think this makes NextDC one of the more interesting tech shares for the next decade.

The world is using more data every year. Cloud computing, artificial intelligence, streaming, cybersecurity, online platforms, and enterprise software all require secure, reliable, high-performance data centre capacity.

NextDC is positioned right in the middle of that demand. The company has been investing heavily to expand its footprint across Australia and into Asia. That can weigh on short-term earnings because data centres require significant upfront capital. But I think the long-term prize could be substantial if demand keeps growing.

What I like about NextDC is that it gives investors exposure to technology infrastructure rather than trying to pick the winning software application.

If more businesses shift workloads to the cloud, if AI adoption increases, and if data intensity keeps rising, high-quality data centre capacity should remain valuable.

Foolish takeaway

Beating the market over 10 years is never guaranteed.

But I think TechnologyOne and NextDC both have qualities that give them a real chance.

TechnologyOne has a repeatable software model, a strong track record, and an overseas growth opportunity. NextDC has exposure to the rising demand for data centre capacity as the digital economy expands.

For investors looking for ASX 200 tech shares to buy and hold, I think both deserve a close look.

The post Why these ASX 200 tech shares could beat the market over the next decade appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: TechnologyOne, Telstra, and Woodside shares
• Top brokers name 3 ASX shares to buy next week
• 3 super ASX tech stocks I’d buy in May with $3,000
• $10,000 invested in these ASX 200 shares 10 years ago is worth…
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Technology One. The Motley Fool Australia has recommended Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two of the ASX’s former market darlings have been brutally sold off over the past year.

Pro Medicus Ltd (ASX: PME) and Xero Ltd (ASX: XRO) have both fallen a long way from their highs, as investors have moved away from expensive growth shares.

But after such large declines, I think both stocks are starting to look very interesting again.

At the time of writing, the Pro Medicus share price is down $128.25. That leaves the medical imaging technology stock down almost 50% over the past year.

Xero shares are trading at $83.43 at the time of writing. The accounting software company has now fallen by around 52% over the past 12 months.

Those steep declines would normally cause investors to panic. But I think this may have created two very attractive buying opportunities in May.

Pro Medicus still has high-quality growth

Pro Medicus has been one of the ASX’s best healthcare technology businesses for years.

The company provides medical imaging software to hospitals, radiology groups, and healthcare networks. Its Visage platform helps manage large volumes of medical imaging data, making it a critical tool within large healthcare systems.

The sell-off has been driven partly by valuation concerns. Pro Medicus was priced for near-perfect growth when the share price was above $300 last year. However, after such a large fall, investors are now getting a much better price for a business that is still delivering strong numbers.

In its HY26 result, Pro Medicus delivered revenue of $124.8 million, up 28.4% year on year. Underlying profit before tax rose 29.7% to $90.7 million, helped by a very high EBIT margin of 73%.

The company has also kept winning major contracts. Recent deals include a 5-year $23 million contract with the University of Maryland Medical System and a 5-year $37 million contract renewal with Northwestern Medicine.

Broker views also remain positive. Recent data shows Morgan Stanley has a $210 price target, while Bell Potter has a $226 target. Based on the current share price, that points to potential upside of about 64% and 76%, respectively.

Xero’s sell-off looks overdone

Xero has had an even rougher year on the share market.

Investors have been worried about slowing software growth, valuation, and whether artificial intelligence (AI) could disrupt accounting platforms.

And that is a fair concern. But Xero is not some fringe software product that can be easily replaced.

Its platform is used for accounting, payroll, payments, tax, invoicing, and cash flow tools. Once a business and accountant are both using Xero, switching can be a hassle.

The latest half-year result showed subscribers up 10% to 4.6 million. Operating revenue rose 20% to NZ$1.19 billion, while net profit after tax (NPAT) jumped 42% to NZ$135 million.

That tells me the business is still growing well, even as the share price says otherwise.

CMC data also points to upside. The average target across recent analyst ratings is $121.78, implying a possible rise of around 46% from the current share price.

The post Down 50%, these 2 ASX growth shares look too cheap to ignore appeared first on The Motley Fool Australia.

More reading

• Are these the 3 most undervalued ASX 200 shares right now?
• Down 40% but not out: Is Pro Medicus the buy of the decade right now?
• Why the ASX 200 is being smashed today
• 3 ASX healthcare shares to buy while they’re on sale
• How much could the Xero share price rise in the next year?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Building wealth for an early retirement often comes down to owning quality investments for the long term. A balanced mix of reliable ASX shares and diversified ETFs can help investors grow passive income, compound returns, and reduce portfolio risk over time.

For Australians targeting retirement earlier than expected, combining defensive infrastructure, blue-chip retailers, and broad-market ETFs may provide a strong foundation.

The following ASX shares and ETFs offer exposure to dividends, international growth, and long-term economic trends that could support a successful retirement strategy.

APA Group (ASX: APA)

APA Group can play an important role in a retirement portfolio thanks to its stable infrastructure earnings and reliable income generation.

The company owns critical gas pipelines and energy assets across Australia, creating a predictable cash flow that supports attractive dividend payments. For retirement-focused investors seeking passive income, APA’s defensive business model may help reduce portfolio volatility during weaker market periods.

While energy regulation and interest rates remain risks, APA continues to benefit from long-term demand for essential infrastructure.

Wesfarmers Ltd (ASX: WES)

Wesfarmers offers retirement investors exposure to some of Australia’s strongest retail and industrial businesses, including Bunnings and Kmart.

The company has a long track record of earnings growth, disciplined capital management, and fully-franked dividends. Those qualities make it a popular core holding for long-term retirement investing.

Wesfarmers also provides diversification across retail, chemicals, healthcare, and industrial operations, helping strengthen portfolio resilience through economic cycles.

Transurban Group (ASX: TCL)

Transurban is another infrastructure giant that may suit retirement investors seeking stable long-term returns.

The company operates major toll roads across Australia and North America, generating recurring revenue linked to population growth and rising traffic volumes.

Infrastructure assets like toll roads often deliver inflation-linked earnings, which can become increasingly valuable during retirement when preserving purchasing power matters.

Although higher interest rates can pressure infrastructure valuations, Transurban’s long-term growth outlook remains attractive.

SPDR S&P/ASX 200 Fund (ASX: STW)

The ASX ETF STW offers investors simple exposure to Australia’s largest listed companies.

For retirement planning, broad diversification can reduce reliance on individual stock performance. STW spreads investments across banks, miners, healthcare companies, and industrial businesses in a single ETF.

The fund also provides dividend income and long-term exposure to Australia’s economy without requiring constant portfolio management.

iShares S&P 500 ETF (ASX: IVV)

This ETF gives retirement investors access to leading US companies, including major technology and consumer brands.

International diversification is important for retirement portfolios because it reduces dependence on the Australian economy alone.

The S&P 500 has historically delivered strong long-term growth, driven by innovation and global corporate leadership. For younger investors targeting early retirement, exposure to high-quality US businesses could significantly boost long-term compounding returns.

Vanguard MSCI Index International Shares ETF (ASX: VGS)

The Vanguard MSCI Index International Shares ETF expands retirement diversification even further by investing across global developed markets.

The ETF holds hundreds of international companies across the US, Europe, and Asia. That global exposure can help smooth returns and provide access to industries less represented on the ASX.

For investors building wealth steadily over decades, VGS may become a powerful retirement compounding tool.

The post Fast-track your retirement with these ASX shares and ETFs appeared first on The Motley Fool Australia.

More reading

• How beginners could go from zero to $50,000 with ASX shares
• How I’d build a simple ASX portfolio with just 3 ETFs
• How to retire early at 57 with these 3 Vanguard ASX ETFs
• Are these the best ASX ETFs to buy with $1,000 now?
• Building wealth with ASX ETFs? Don’t make these errors

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Transurban Group, Wesfarmers, and iShares S&P 500 ETF. The Motley Fool Australia has positions in and has recommended Apa Group and Transurban Group. The Motley Fool Australia has recommended Vanguard Msci Index International Shares ETF, Wesfarmers, and iShares S&P 500 ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Western Australia-based drone technology company Boresight Ltd (ASX: BST) is looking to raise $8 million ahead of a listing on the ASX next month.

Drone targets the differentiator

The company said in its prospectus lodged with the ASX that it was incorporated in 2020, “with the purpose to provide low-cost aerial drone targets to service western and allied militaries as they tackle how to respond to the rapidly changing battlespace”.

The company said further:

Military customers require a cost-effective and reliable way to evaluate counter drone technologies. Once these capabilities are deployed, they must develop effective tactics, techniques and procedures (TTP’s) for their use, and undertake continuous training to ensure that personnel are properly trained, and maintain those skills, throughout the life of the technology. To achieve this, customers require low-cost, disposable training drones (targets) – and lots of them. Boresight was created to meet that need.

The company said it provides target drones which emulate real-world threats, “in a reliable and repeatable manner, at a price point that supports live-fire, testing, destructive evaluation and training without placing undue pressure on defence budgets”.

The company said:

Considerable investment has been made into the optimisation of the manufacture of the target drones, allowing easy scaling of the manufacturing process to meet demand. More recently, Boresight also expanded into ISR Drones (also known as ‘camera drones’), which are designed specifically as cost-effective camera drones designed for missions where a live video feed from the drone is required.

Boresight said it had sold more than 6,000 drones to customers globally since its launch and had offices in the US, the United Kingdom, and Australia.

The company has sold drones to 15 militaries across 12 countries, “and has recently commenced low-rate manufacturing in the United States to support local customers”.

Growing market

The prospectus said the market will continue to evolve, with aerial targets of different sizes and complexity needed in the future.

It also said many Western militaries have moved away from using Chinese-manufactured drones for security purposes.

The funds raised will be used to expand the company’s engineering and production teams, ramp up production in the United States, increase its additive manufacturing capacity, and further vertically integrate operations.

The company expects to have $8.94 million in cash following the capital raise and to be valued at $48.8 million.

Boresight generated $4.36 million in revenue in FY25, up from $2.77 million, and posted a loss of $596,421, the prospectus said.

The capital raise is expected to close on May 19, with the shares to start trading on the ASX on June 10.

The post Let’s have a look at the latest drone company looking to list on the ASX appeared first on The Motley Fool Australia.

More reading

• Why these ASX 200 tech shares could beat the market over the next decade
• Down 50%, these 2 ASX growth shares look too cheap to ignore
• Fast-track your retirement with these ASX shares and ETFs
• Are these the 3 most undervalued ASX 200 shares right now?
• 3 ASX ETFs for investors in their 60s

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The turbulent 2026 for the S&P/ASX 200 Index (ASX: XJO) has been somewhat of a rollercoaster for investors. 

However, it has also created rare buying opportunities for some of the country’s biggest companies. 

After a difficult 12 months, including heavy losses this year, here are three of the most undervalued ASX 200 stocks. 

REA Group Ltd (ASX: REA)

REA Group operates one of Australia’s most recognisable online real estate advertising companies. 

Its share price has fallen 33% from yearly highs. 

However, a recent update from the team at Bell Potter indicates it could be a rare opportunity to scoop up this ASX 200 stock at a considerable discount. 

As James Mickleboro reported yesterday, Bell Potter said that REA Group delivered a strong and resilient third-quarter result despite higher interest rates. 

Listings grew 1%, supported by strong performance in Melbourne and Sydney, while revenue from residential, commercial, and financial services all performed well. 

The broker also noted that cost growth was controlled, helping profit margins improve significantly.

Bell Potter was particularly positive about REA Group’s pricing power, noting that the company plans to increase prices by 8% in FY27, compared to rival Domain Holdings Australia planning only a 4% increase. 

Bell Potter believes this shows REA remains confident in the value of its platform and its dominant audience reach.

While the broker expects property listings to decline slightly in FY27, it believes the housing market is moving into a more balanced phase after a period of very strong demand.

This culminated in an increased price target of $217, which indicates a 23% upside from current levels. 

WiseTech Global Ltd (ASX: WTC)

Moving to the technology sector, WiseTech Global shares are down nearly 40% year to date. 

The logistics software provider now appears to sit firmly in the value window. 

Yesterday, Aaron Teboneras laid out the bull case for a rebound. 

Its sticky customer base and implied EBITDA margin of around 40% to 41% in FY26 make current valuations look particularly appealing. 

This ASX 200 stock is currently trading around $42.36 per share. 

This is more than 80% below recent target prices from brokers. 

Pro Medicus Ltd (ASX: PME)

Finally, in the struggling healthcare sector, Pro Medicus shares appear to be well below fair value. 

The medical imaging technology company has continued to secure blue-chip contracts and has experienced strong growth this year. 

Pro Medicus software becomes deeply embedded in hospital imaging workflows, making the systems difficult to replace and creating strong switching costs alongside reliable recurring revenue streams.

In its HY26 result, this operating model has led to revenue growth of 28.4% to $124.8 million, while underlying profit before tax climbed almost 30%.

Despite these green flags, its share price is down more than 40% year to date. 

At the time of writing, it is trading at roughly $129 per share. 

Recent broker estimates have placed fair value at $200 per share, making current prices a tempting entry point. 

The post Are these the 3 most undervalued ASX 200 shares right now? appeared first on The Motley Fool Australia.

More reading

• Where to invest $20,000 in ASX 200 shares this week
• Leading brokers name 3 ASX shares to buy today
• Down 40% but not out: Is Pro Medicus the buy of the decade right now?
• Why the ASX 200 is being smashed today
• 3 ASX healthcare shares to buy while they’re on sale

Motley Fool contributor Aaron Bell has positions in WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Investing in your 60s can require a different mindset.

At that stage, I think many investors still want growth, but they may also care more about income, diversification, and avoiding unnecessary risk.

That does not mean moving everything into cash. Retirement can last decades, so growth still has a role to play. But I think the balance needs to be more thoughtful.

For investors looking for exchange-traded funds (ETFs), three ASX ETFs stand out to me.

Vanguard Australian Shares High Yield ETF (ASX: VHY)

The first ETF I would consider is the Vanguard Australian Shares High Yield ETF.

As the name suggests, this fund focuses on Australian shares with higher expected dividend yields.

I think that can make it useful for investors in their 60s who want their portfolio to produce income without having to pick every dividend stock themselves.

The ASX has a strong dividend culture. Banks, miners, insurers, infrastructure shares, and other mature businesses often return a meaningful portion of profits to shareholders.

The VHY ETF gives investors a way to access a diversified basket of these income-paying companies.

There are risks. A high yield does not automatically mean a safe yield. Some sectors can be cyclical, and dividends can be cut when earnings fall.

But as part of a broader portfolio, I think the Vanguard Australian Shares High Yield ETF can be a sensible way to generate income from Australian shares while still keeping some exposure to capital growth.

Vanguard Diversified Conservative Index ETF (ASX: VDCO)

The second ETF I would look at is the Vanguard Diversified Conservative Index ETF.

This is a very different type of fund. The VDCO ETF is designed for investors with a lower tolerance for risk. It targets a 70% allocation to income assets and a 30% allocation to growth assets.

That kind of split could make sense for investors in their 60s who want a steadier ride than a share-heavy portfolio may provide.

The ETF invests across a range of underlying funds, giving investors broad diversification across different asset classes. In other words, it is not just about owning Australian shares or global shares. It also includes income assets that can help reduce volatility.

I think that simplicity is appealing. Rather than trying to build a diversified conservative portfolio from scratch, investors can use the VDCO ETF as a ready-made option.

It currently trades with a trailing dividend yield of around 3.5%, which may also appeal to investors looking for income. While this yield is lower than some share-focused income ETFs, the trade-off is a more defensive asset mix.

iShares Global Consumer Staples ETF (ASX: IXI)

The third ETF I would consider in my 60s is the iShares Global Consumer Staples ETF.

This fund provides exposure to global consumer staples companies. I think that is an interesting area for investors nearing retirement because consumer staples businesses tend to sell products people buy in most economic environments. This can include food, drinks, household goods, and personal care products.

These are rarely the most exciting companies on the market. But that is part of the appeal.

During tougher economic periods, consumers may delay buying a new car, renovating a house, or booking a luxury holiday. But they still need groceries, cleaning products, and everyday essentials.

That can give consumer staples companies a more defensive earnings profile.

The IXI ETF also provides global diversification, which is useful for Australian investors. The local market is heavily weighted toward banks and miners, so adding global staples exposure can help broaden a portfolio.

Foolish Takeaway

For investors in their 60s, I think the best ETF portfolio is one that balances income, resilience, and enough growth to keep working over time.

None of these ETFs removes risk completely. But together, I think they could help investors build a portfolio that is more suited to the retirement years than a pure growth strategy.

The post 3 ASX ETFs for investors in their 60s appeared first on The Motley Fool Australia.

More reading

• Building wealth with ASX ETFs? Don’t make these errors
• How to build a $1,000 a month passive income from the ASX
• How to make $12,000 of passive income from these ASX ETFs
• How much do I need to invest in ASX dividend shares for a retirement income of $5,000 per month?
• 3 strong ASX ETFs to buy and hold for a decade or more

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Vanguard Australian Shares High Yield ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.